Braveheart Bio, Inc. (BRVE)
NASDAQ: BRVE · Real-Time Price · USD
19.55
+0.21 (1.09%)
At close: Oct 15, 2026, 4:00 PM EDT
19.27
-0.28 (-1.43%)
After-hours: Oct 15, 2026, 7:30 PM EDT
Company Description
Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases.
It develops and offers BHB-1893 and HRS-1893, an oral small-molecule cardiac myosin inhibitor (CMI) for the treatment of obstructive HCM and non-obstructive HCM.
The company was incorporated in 2024 and is headquartered in San Francisco, California.
Braveheart Bio, Inc.
| Country | United States |
| Founded | 2024 |
| IPO Date | Aug 6, 2026 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 49 |
| CEO | Travis Murdoch |
Contact Details
Address: One Letterman Drive, Building A San Francisco, California 94129 United States | |
| Phone | 415 707 6312 |
| Website | braveheart.bio |
Stock Details
| Ticker Symbol | BRVE |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $18.00 |
| CIK Code | 2131524 |
| CUSIP Number | 10567X101 |
| ISIN Number | US10567X1019 |
| Employer ID | 99-2981994 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Travis Murdoch B.S., M.D., M.Sc. | Chief Executive Officer, President and Director |
| James Paul Rickey CPA | Chief Financial Officer |
| Michele A. Anderson | Chief Development Officer |
| Marc Evanchik M.S. | Chief Scientific Officer |
| Natalie Dement J.D. | Vice President and Head of Legal |
| Timothy Y. Zhou | Director of Corporate Development |
| Steph Palencia | Associate Director of Human Resources and Office Manager |
| Brittany de Temple | Senior Vice President of Development Operations |
| Dr. Emil M. deGoma M.D. | Chief Medical Officer |
| Tyler Chavez Ph.D. | Chief Business Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 10, 2026 | SCHEDULE 13D/A | Filing |
| Sep 8, 2026 | 10-Q | Quarterly Report |
| Sep 8, 2026 | 8-K | Current Report |
| Aug 18, 2026 | SCHEDULE 13D | Filing |
| Aug 14, 2026 | SCHEDULE 13D | Filing |
| Aug 14, 2026 | SCHEDULE 13G | Filing |
| Aug 7, 2026 | 8-K | Current Report |
| Aug 6, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Aug 6, 2026 | 424B4 | Prospectus |
| Aug 6, 2026 | CERT | Certification by an exchange approving securities for listing |